MUSC named to the Forbes 2019 list of America’s Best Large Employers see more
The Medical University of South Carolina (MUSC) has been ranked No. 267 out of 500 organizations on the Forbes 2019 list of America’s Best Large Employers. MUSC is one of only 22 organizations included in the Healthcare & Social category. This is the second time MUSC has appeared on this annual Forbes list, which pinpoints the companies liked best by employees.
“Employee engagement and satisfaction are critical elements in achieving any organization’s success in both the short term and long term,” said MUSC President David J. Cole, M.D., FACS. “This recognition is a valuable acknowledgment of our ongoing efforts to provide every employee with a work environment where they are supported, appreciated and part of positive, life-changing teams.”
Collaborating with market research firm Statista, Forbes surveyed more than 50,000 employees working at U.S. companies and organizations with at least 1,000 people. The survey was conducted with global digital data collection partners who use innovative technology and proven sampling methodologies to facilitate a deep understanding of consumer opinions and behavior. Participation in the survey was voluntary, and respondents were recruited from thousands of sources to maximize reach and representation.
The survey included more than 30 detailed questions about working conditions. In addition, the American employees were asked to determine, on a scale of zero to 10, how likely they were to recommend their employers to someone else. The survey also stratified workers’ responses on topics like innovation, remuneration, benefits and atmosphere. Further, they were asked how they feel about the other employers in their respective industries. The mix of respondents (gender, age, region and ethnicity) in the sample represents American employees.
About The Medical University of South Carolina
Founded in 1824 in Charleston, MUSC is the oldest medical school in the South, as well as the state’s only integrated, academic health sciences center with a unique charge to serve the state through education, research and patient care. Each year, MUSC educates and trains more than 3,000 students and 700 residents in six colleges: Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy. The state’s leader in obtaining biomedical research funds, MUSC brought in more than $276.5 million in fiscal year 2018.
As the clinical health system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality patient care available, while training generations of competent, compassionate health care providers to serve the people of South Carolina and beyond. Comprising some 1,600 beds, more than 100 outreach sites, the MUSC College of Medicine, the physicians’ practice plan, and nearly 275 telehealth locations, MUSC Health owns and operates eight hospitals situated in Charleston, Chester, Florence, Lancaster and Marion counties. In 2018, for the fourth consecutive year, U.S. News & World Report named MUSC Health the number one hospital in South Carolina. To learn more about clinical patient services, visit http://muschealth.org.
MUSC and its affiliates have collective annual budgets of $3 billion. The more than 17,000 MUSC team members include world-class faculty, physicians, specialty providers and scientists who deliver groundbreaking education, research, technology and patient care. For information on academic programs, visit musc.edu.
Harbor Entrepreneur Center gains new leader see more
The Harbor Entrepreneur Center, a nonprofit focused on helping entrepreneurs through accelerator programs and coworking spaces, will have a new executive director on June 1.
Daniel Stern, the former executive director of the Jewish Community Center and previous major gifts officer for the Lowcountry Food Bank, will assume the helm. John Osborne, the Harbor’s co-founder and current executive director, said recently he plans to step down to work fulltime at Good Growth Capital, a Charleston-based venture capital fund, and with Charleston Angel Partners, an area investment group. “The Harbor is heading into a phase of rapid growth and we are excited to have Daniel on board to lead our nonprofit,” said Osborne, who will sit on the board.
SCBIO's Charleston-area office is graciously hosted at The Harbor Entrepreneur Center by the non-profit organization.
HOTH THERAPEUTICS SIGNS TERM SHEET WITH ZYLÖ THERAPEUTICS TO ACQUIRE A LICENSE AND JOINTLY DEVELOP A PRODUCT TO TREAT LUPUSSouth Carolina's Zylo Therapeutics partners with Hoth on lupus treatment see more
NEW YORK, May 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that the company has signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE). CLE is a chronic autoimmune disease that affects the skin.
Zylö, dedicated to bringing innovative technologies to multiple facets of medicine, has an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented xerogel-derived nanoparticles, called Z-pods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. For more information, please visit; http://www.zylotherapeutics.com/
Scientists at Einstein College of Medicine recently demonstrated that topical administration with AEA-loaded nanoparticles significantly prevents the development of CLE in an established animal model of lupus. This work reinforces and highlights the utility of targeting the endocannabinoid system for autoimmune rheumatic diseases.
The work at Einstein supports the thesis that AEA loaded into Z-pods™ improves drug skin penetration, reduces the expected inflammatory cytokine secretion by keratinocytes when exposed to ultraviolet radiation, prevents the development of CLE skin lesions, improves skin histopathology, prevents inflammation and structural damage on histology and reduces macrophages and C3 accumulation.
According to estimates by the Lupus Foundation of America (LFA), 1.5 Million Americans currently suffer from lupus, with 16,000 new cases reported annually. Tragically, lupus strikes mostly women of child-bearing age. Worldwide, the LFA estimates that at least five million people may have some form of the disease. Of the people diagnosed, approximately two-thirds will develop CLE. The annual average cost to provide medical treatment for a person with lupus: $6,000 to $10,000, with some treatment costing several thousand dollars a month.
"Management is extremely pleased to partner with Zylö Therapeutics, enhancing our portfolio of unique treatments for patients suffering from various dermatological related ailments," stated, Mr. Robb Knie, CEO of Hoth Therapeutics. "Zylö's initial work shows significant promise in combating Cutaneous Lupus Erythematosus, and we look forward to working with them in order to bring this treatment to market."
"We are thrilled to partner with Hoth, a company that is committed to innovative solutions and partnerships to develop treatments for diseases with a high unmet clinical need, such as lupus," said Scott Pancoast, CEO of Zylö. "As we work with the Hoth team to advance AEA-loaded Z-pods through the next stages of development, we expect to further demonstrate the important role that our patented Z-pod delivery system plays in improving treatment outcomes."
The term sheet is non-binding and neither party thereto shall have any obligation to consummate a transaction of any kind until such time as the parties have entered into a mutually agreeable definitive agreement. There can be no assurance that any such definitive agreement will be entered into or that the transaction will be completed on the terms set forth in the term sheet, or at all.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.
SCBIO's Sam Konduros updates viewers on the advancements that the life sciences industry is making. see more
SCBIO CEO Sam Konduros joins Carolina Business Review moderator Chris William for an interview airing recently across the Carolinas on the rapid growth and momentum that life sciences is experiencing across the Palmetto State, and some of the challenges in dealing with that growth. CBR is the most widely watched source for business and public policy issues across North and South Carolina. Click here to enjoy the complete interview on YouTube.
Nephron initiates EDI through Global Healthcare Exchange see more
Nephron Pharmaceuticals Corporation initiated Electronic Data Interchange (EDI) ordering through the Global Healthcare Exchange, LLC (GHX) platform, accessible immediately.
Joining GHX allows Nephron customers to purchase products on the FDA drug shortage list in one simple step. This platform enables purchasers to select products from multiple vendors in one place, rather than logging in to the Nephron online ordering system. Utilizing the GHX cloud-based platform helps to reduce manual work and provides real-time data to view and validate order information. Nephron and its customers are working in real time, using all available data to streamline each process.
“Nephron is constantly trying to improve the customer experience,” said Hank Jibaja, Chief Information Officer at Nephron. “We believe utilizing the GHX platform will decrease the time required from the hospital or ordering staff.”
Nephron products including Sodium Bicarbonate, Phenylephrine, Labetalol and more are available for purchase through the GHX platform.
Hospitals and surgery centers may contact Nephron toll free at 1-800-443-4313, or via email at firstname.lastname@example.org.
Nephron 503B Outsourcing is a division of Nephron Pharmaceuticals Corporation. This division produces pre-filled sterile syringes and IV bags for hospitals and surgery centers across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration as a sterile manufacturer of generic respiratory medications along with an Outsourcing Facility providing equal sterility and quality. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.
Global Healthcare Exchange, LLC (GHX) is a healthcare business and data automation company, empowering healthcare organizations to enable better patient care and maximize industry savings using its world-class cloud-based supply chain technology platform. GHX brings together healthcare providers, manufacturers and distributors in North America, and Europe, who rely on proven healthcare-focused technology and comprehensive data to automate business processes and make more informed, timely and fact-based decisions. Solutions span procurement and accounts payable automation, contract and inventory management, vendor credentialing and management, business intelligence, payment management and other supply chain-related tools and services. For more information, visit www.ghx.com and The Healthcare Hub.
KIYATEC Announces $3 Million Initial Closing of Series B2 Preferred Stock Financing and New Investor LabCorpKIYATEC closes on new round of financing see more
GREENVILLE, SC. – May 1, 2019 – KIYATEC, Inc. today announced the initial $3 million closing of the company’s series B2 financing round. The round was led by VentureSouth and included LabCorp® (NYSE: LH).
“This validation and confidence by our investors, coupled with the exciting progress of our clinical trials, puts us on the path toward the next phase of growth and development,” said Matthew Gevaert, CEO of KIYATEC. “We are particularly excited to welcome LabCorp as a new investor because of the depth and breadth of their expertise in oncology. With the preclinical and clinical development strengths of LabCorp’s Covance Drug Development business, and their corporate position as a world leader in clinical testing, there is great potential synergy across the many ways KIYATEC’s technology can be used to improve cancer care.”
Proceeds from the financing will go toward KIYATEC’s ongoing clinical study, 3D-PREDICT, to validate KIYATEC’s proprietary assay as a patient-specific predictor of response to cancer therapies for solid tumors. The test analyzes a patient’s live cancer cells, grown in KIYATEC’s laboratory within a biologically relevant 3D microenvironment, to determine whether those cells respond to guideline-recommended cancer drugs. The 3D-PREDICT study is a fully prospective, multi-institutional effort to validate the predictive accuracy of the test and correlate response predictions to clinical outcomes among patients with newly diagnosed and relapsed ovarian cancer, glioblastoma and certain rare tumors.
The company has gained significant momentum in 2019. Recently, at the 110th Annual Meeting of the American Association for Cancer Research (AACR), KIYATEC demonstrated leading capabilities in modeling and predicting response to immuno-oncology therapies including checkpoint inhibitors. On April 10, KIYATEC was one of 20 companies recognized nationally on Capitol Hill as part of the 2019 University Innovation & Entrepreneurship Showcase. In the first quarter of 2019, KIYATEC added three clinical sites to its 3D-PREDICT study and expects to continue its momentum by adding additional sites in the second and third quarters.
About KIYATEC, Inc.
KIYATEC is dedicated to accurately modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision making and drive drug development. Our predictive clinical tests provide oncologists with patient-specific response profiles to current standard of care drugs prior to treatment selection. Our predictive 3D models are being used by leading biopharmaceutical companies to increase the success of their preclinical and clinical drug development programs as they develop the cancer therapies of the future. www.kiyatec.com.
Top Clemson alumni honored for accomplishments, contributions see more
Their faces lit up the scoreboard, they patted Howard’s Rock and they celebrated by the end zone.
Some of Clemson University’s top alumni gathered in Memorial Stadium on the night of April 25 for the annual showcase gala of the College of Engineering, Computing and Applied Sciences. Three of the college’s alumni were inducted into the Thomas Green Clemson Academy of Engineers and Scientists, while three others were celebrated as Outstanding Young Alumni.
The 2019 honorees posed for a picture with Dean Anand Gramopadhye after a gala at Memorial Stadium. The newest academy members are I.V. Hall, Denise Rutledge Simmons and Vanessa Ellerbe Wyche. This year’s crop of Outstanding Young Alumni are Chelsea L. Ex-Lubeskie, Allison Godwin and Amol V. Janorkar. Continue reading the entire story here.
Commerce Office of Innovation introduces Scribble for the innovation community see more
COLUMBIA, S.C. - The S.C. Department of Commerce's Office of Innovation today announced the launch of Scribble - an online tool for the state's innovation community. Providing individuals and businesses a platform to access resources, this new site is designed to highlight South Carolina's exceptional ingenuity and create a common place for users to access a variety of helpful tools.
"South Carolina's burgeoning innovation sector has come a long way, and this new, state-of-the-art platform will ensure that entrepreneurs have all they need to thrive," said Secretary of Commerce Bobby Hitt. "Inspired by our human nature to document or write down that 'ah-ha' moment, we're excited to celebrate our innovators through Scribble."
With access to company video features, podcasts, blogs and events, Scribble allows users to create a profile to save resources and content, further enhancing the innovation community's connectivity. Launched at the 2019 DigSouth Tech Summit in Charleston, S.C., Scribble will help innovators connect with startup programs, venture capital and other resources around the state.
For more information, visit www.scribblesc.com.
MUSC continues advances in telehealth see more
The Medical University of South Carolina has received a $3.6 million grant to support the development of a national telehealth research network.
As opposed to supporting a specific clinical research study, the grant seeks to establish an easily accessible support structure around telehealth research, including tools, resources, collaboration, education and advocacy materials to anyone across the country who wants to study telehealth programs.
“We expect this network to become the preeminent source for evidence-based policy and outcomes data,” said Brook Yeager McSwain, health policy consultant for the project and manager of the S.C. Children’s Telehealth Collaborative, in a news release. “Our national and state legislators have seen the benefits of telehealth for certain populations and regions. We have to demonstrate to them that this works across the country and has the potential to dramatically impact health care delivery models.”
The five-year National Institutes of Health grant builds on work already underway as part of the Supporting Pediatric Research on Outcomes and Utilization of Telehealth project, known as Sprout. The grant will support telehealth research efforts, metric development, identification of best practices and the development of collaborative policy and advocacy materials across the country.
Sprout is a network of institutions and pediatric providers operating within the American Academy of Pediatrics, which is a sub-awardee of the grant. The other sub-awarded institutions are the University of Colorado – Children’s Hospital Colorado, Children’s Hospital of Philadelphia and Mercy Hospital in St. Louis.
“This is a huge step forward in the development of safe and impactful telehealth programs across the country,” said Dr. S. David McSwain, the primary investigator for the NIH grant, in the release. “Academic research into the real impact of telehealth services is a critical component of developing and growing programs with the greatest potential to improve our health care system.”
In 2015, McSwain, who is also an MUSC Children’s Health physician, MUSC chief medical information officer and associate professor of pediatric critical care, collaborated with a small group of pediatric physicians across the country to form Sprout, which has since completed and published the nation’s first broad assessment of pediatric telehealth infrastructure across the country.
The grant is a Collaborative Innovation award through the National Center for the Advancement of Translational Science. The program will operate in collaboration with Clinical and Translational Science Awardsites across the country to facilitate research development and support telehealth researchers to develop projects and find funding.
Workforce a focus for Upstate South Carolina initiative see more
UPSTATE, S.C., APRIL 17, 2019 — Upstate industries have invested more than $20 billion and announced nearly 63,000 new jobs in the last 13 years.
To help Upstate employers sustain their economic momentum, the Upstate SC Alliance launched a regional talent attraction initiative at its 2019 Annual Meeting, with nearly 500 business leaders in attendance.
The initiative, “Move Up” includes a brand and website, MoveUpstateSC.com, which promote job opportunities and quality of life across the 10-county Upstate region.
“Workforce has quickly become a top factor as companies consider whether to locate or expand in our region,” said John Lummus, Upstate SC Alliance President & CEO. “Our region has the right ingredients not only to meet business needs, but also to provide fulfilling careers and a rich lifestyle. Move Up is here to help employers and our communities tell that story.”
Upstate employers can use MoveUpstateSC.com while recruiting candidates in a variety of professional fields, including: manufacturing + engineering; financial services; information + communications technology; education; life sciences + healthcare; architecture, construction + engineering; and creative services.
The Upstate SC Alliance worked with Development Counsellors International (DCI) to create the Move Up brand and website, with support from the Anderson Area Chamber of Commerce, the Greenville Chamber of Commerce, the Spartanburg Area Chamber of Commerce and Ten at the Top.
Target audiences include established professionals in multiple industries and college students looking to launch their careers.
The website includes interactive community profiles, facts and stats about Upstate living, an overview of industries, and a job board.
In addition to the resource being a tool for Upstate employers, it will be supported by a digital marketing campaign.
Nephron CEO Lou Kennedy honored with national award see more
Nephron Pharmaceuticals President and CEO Lou Kennedy was honored on Thursday by the National Association of Manufacturers (NAM) with an award for outstanding leadership in manufacturing. Ms. Kennedy is also the Board Chair of South Carolina's life sciences organization, SCBIO.
NAM recognized Kennedy at its Manufacturing Institute’s STEP Ahead Women’s Initiative. One of NAM’s largest annual events, the STEP Ahead Award celebrates the achievements of women in manufacturing who inspire the next generation to follow in their footsteps.
“Nephron is a global leader in pharmaceutical manufacturing, and I am grateful to NAM for recognizing the great work of our team of professionals that delivers safe, effective and affordable medications to patients across the world,” said Kennedy.
Nephron is a certified woman-owned business, as recognized by the National Women Business Owners Corporation (NWBOC), the first certifier of Women Business Enterprises. The certification gives Nephron enhanced visibility and a competitive edge.
Nephron’s workforce is forty-four percent women, holding the majority of all advanced degrees at the company. Additionally, women hold key management roles in various departments throughout Nephron, such as Quality Assurance, Chemistry and Microbiology, Regulatory Compliance, Human Resources, Training, R&D Engineering, and Product Development.
Nephron Pharmaceuticals Corporation develops and manufactures safe, affordable generic inhalation solution and suspension products specializing in Blow-Fill-Seal technology. In addition, the company operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.
Chromasol's LightGuard antimicrobial technology selected by Akzo Nobel as a finalist in "Let's Paint The Future!" global contestChromasol chosen by Akzo Nobel as a finalist in "Let's Paint The Future!" global contest see more
Chromasol's LightGuard antimicrobial technology has been selected by Akzo Nobel as a finalist in their "Let's Paint The Future!" global contest, executives with Chromasol have announced. For complete details on this prestigious competition and on Chromasol's entry, click here to read on.
FDA Approves Amgen's EVENITY™ for Treatment of Osteoporosis in Postmenopausal Women at High Risk for FractureEVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy see more
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture. A full course of EVENITY therapy is 12 monthly doses administered by a healthcare provider.2 Since osteoporosis is a chronic disease, continued therapy with an anti-resorptive agent should be considered once EVENITY therapy is completed.
University of South Carolina Opens Innovation Think Tank Lab in Partnership with Siemens HealthineersSiemens Healthineers and USC have forged a new partnership see more
The University of South Carolina has opened its Innovation Think Tank (ITT) Lab in downtown Columbia in collaboration with Siemens Healthineers. The space will be an innovation hub where participants including researchers, faculty members, and students can think outside the box to solve issues in healthcare, artificial intelligence, robotics, and information technology. The ITT Lab at South Carolina is the first Innovation Think Tank Lab affiliated with a U.S. university, as part of Siemens Healthineers' global network of Innovation Think Tank Labs led by adjunct professor Sultan Haider.
"Centers like this are so important because they bring technology and use it to create something new and do things differently," said Elizabeth Regan, the chair of Integrated Information Technology at the College of Engineering and Computing. "That involves opening your mind, moving yourself out of your comfort zone, innovative thinking, and collaborating."
Computer science professor Neset Hikmet, who oversaw the lab's creation, said his vision for the lab is to host workshops with participants from diverse academic backgrounds and to provide them with mentorship and resources to solve pressing issues in healthcare and beyond. "These are all opportunities that have participants getting out of their boundaries, meeting different people, and experiencing different cultures and ways of doing things," Hikmet said.
Hossein Haj-Hariri, dean of the College of Engineering and Computing, noted the importance of the university's growing partnership with Siemens. "The focus of Siemens Healthineers is very much aligned with that of modern curricula, which stress design thinking in addition to coverage of the fundamentals," Haj-Hariri said. "Furthermore, the innovation process underpinning Healthineers and ITT provides a natural platform for imparting to the participants the soft skills necessary for success in the 21st century."
Dilek Akgun, director of operations at the ITT Lab, said that this new facility will promote creative thinking in the future. "The ITT Lab will allow us to bring people together from a variety of disciplines to share their unique perspectives, which will stimulate innovation and help great ideas become reality," Akgun said.
Thanks to the UofSC ITT Lab's affiliation with Siemens Healthineers' global ITT infrastructure worldwide, the participants will be able to share knowhow with other ITT members and participate at its various locations in Germany, the U.K., China, Turkey, India, and the U.S. This global network will allow participants to collaborate with other innovators worldwide.
Siemens Healthineers' ITT Lab founder and director Haider, who is also now affiliated with the College of Engineering and Computing as an adjunct professor to help with the successful implementation of the lab, heads Siemens Healthineers' ITT global organization from Germany. Haider noted the benefits that students will see from this new partnership. "In addition to many new learning possibilities, the UofSC ITT lab's top participants will have the potential for receiving a variety of fellowships and internships with the Siemens Healthineers ITT lab global network," Haider said.
In conjunction with the opening of the ITT Lab, 20 participants from academic institutions such as South Carolina, Georgia Tech, Benedict College, and the University of Florida participated in a two-day "Interdisciplinary Innovations in Healthcare Workshop." There, the participants were challenged to identify a problem in the healthcare industry and then develop and present a real-world solution to that problem.
In just two days' time, these participants' ideas showed the possibilities of this new lab organized around innovation. Their ideas included an app for stroke detection and monitoring in real-time, an implant that holds patients' medical history, and a smart pill that treats obesity.
Clemson and Arthrex are launching a program to teach students and support the med device industry see more
The surgical device industry is continuously growing and evolving. According to data from GlobalData, the orthopedics market is expected to grow to $66 billion by 2023 from $52.8 billion in 2017. In South Carolina, medical devices are an anchor of the state's fast-growing and globally respected life sciences industry, according to executives with SCBIO -- the Palmetto State's life sciences industry organization and champion.
In response to this upward trend, surgical device companies are seeking more employees with a specialized skillset, and thanks to a new partnership with Arthrex Inc., Clemson University students will be equipped to answer the call.
A global leader in minimally invasive orthopedics, Arthrex already works with Clemson on a number of research projects. Now it’s expanding its engagement with the university through a new, two-year pilot program developed with the needs of the surgical device industry in mind and a generous gift of ten $7,500 scholarships.
“Arthrex is one of the university’s valuable strategic partners, and this opportunity to work together to create programming unique to Clemson speaks volumes about what the company thinks of our talented faculty and students,” said Clemson President James P. Clements. “This partnership is another example of Clemson’s ongoing commitment to the state of South Carolina, and I am grateful to Arthrex for its generous gift, which will enable our students to work with a world-class company to develop skills that are vital to the surgical device industry.”
“Arthrex takes great pride in its commitment to education and we are pleased to help develop the next generation of highly skilled professionals like Arthrex Technology Consultants who work with orthopedic surgeons to provide trustworthy technical product support,” said Arthrex President and founder Reinhold Schmieding.
In October 2017, Arthrex announced plans for a new $40 million facility in Sandy Springs, South Carolina. Surgical devices will be manufactured in the 290,000-square-foot facility, which is scheduled to open this summer. The new location is part of Arthrex’s efforts to expand its manufacturing base into South Carolina to create new products and jobs in America.
The pilot program will span two years and comprise a series of courses, Arthrex internships and additional learning opportunities for rising third-year students majoring in bioengineering, marketing and health sciences departments.
MKT 4950 Developing and Selling Medical Devices is the first course being offered in the series and will begin in fall 2019. Taught by Ryan Mullins in the College of Business, course material provides students an introduction to the health care industry with a focus on the development and marketing of surgical device innovations. Mullins was selected to develop the course as the Provost’s Inaugural Innovation Fellow, a program created to encourage faculty on campus to support corporate engagement efforts.
“Our collaboration with Arthrex helps us create a new type of focused course,” said Mullins. “We will walk students through real case studies at Arthrex to understand how surgical devices get translated from marketable idea to surgeon or physician adoption. This helps us illustrate the challenges inherent to both the health care marketplace and marketing of new offerings, which is not taught anywhere else.”
Students who are enrolled in the course may apply for the scholarship and additional programs offered as part of the two-year series of courses. Those who would like to participate in the entire program will take Student Affairs’ Certified Student Leader Program in the spring and an internship with Arthrex in the summer. Students outside of the participating departments can also intern with Arthrex by working with their advisers and the career center.
This partnership was developed through Clemson’s Office of Corporate Partnerships and Strategic Initiatives. Additional details regarding the scholarship, internship and second-year courses will be available soon.